ClinicalTrials.gg
Status unknownNCT05465707Updated Jul 20, 2022

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

A Phase 1/2 interventional study of CM313 2 mg/kg and CM313 4 mg/kg in Systemic Lupus Erythematosus, sponsored by Keymed Biosciences Co.Ltd. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A study of CM313 in subjects with systemic lupus erythematosus

Read the detailed description

This is a multi-center, randomed, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, Pharmacokinetics and preliminary anti-tumor activity.

About 40 patients who meet eligibility criteria will be randomized 4:1 to receive either CM313 or matched placebo, intravenous infusion.

The treatment period includes single dosing and multiple dosing period, in which CM313 and placebo will be adminitrated intravenously, once every 1 week.

02

Conditions studied

  • Systemic Lupus Erythematosus
03

In context

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's planned enrollment of 40 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤ age ≤ 65 years old.
  • Positive autoantibody serology test at screening.
  • .
  • Voluntarily sign the ICF.

Exclusion criteria

Exclusion Criteria:

  • With central nervous system disease caused by or not caused by SLE within 8 weeks before the first dose of study drug.
  • Possibly active Mycobacterium tuberculosis infection.
  • With the history of vital organ transplantation or hematopoietic stem cell/or bone marrow transplantation.
  • Heavy drinking in the 3 months prior to screening.
  • With depression or suicidal thoughts.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    CM313 2 mg/kg

    Once 1 week, intravenous infusion.

    Biological: CM313 2 mg/kg

  • Experimental
    CM313 4 mg/kg

    Once 1 week, intravenous infusion.

    Biological: CM313 4 mg/kg

  • Experimental
    CM313 8 mg/kg

    Once 1 week, intravenous infusion.

    Biological: CM313 8 mg/kg

  • Experimental
    CM313 16 mg/kg

    Once 1 week, intravenous infusion.

    Biological: CM313 16 mg/kg

  • Placebo comparator
    Placebo

    Once 1 week, intravenous infusion.

    Biological: Placebo

Interventions

  • BiologicalCM313 2 mg/kg

    Drug page: Lumrotatug

    Once 1 week, intravenous infusion.

  • BiologicalCM313 4 mg/kg

    Drug page: Lumrotatug

    Once 1 week, intravenous infusion.

  • BiologicalCM313 8 mg/kg

    Drug page: Lumrotatug

    Once 1 week, intravenous infusion.

  • BiologicalCM313 16 mg/kg

    Drug page: Lumrotatug

    Once 1 week, intravenous infusion.

  • BiologicalPlacebo

    Once 1 week, intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs).

    Safety parameters

    Time frame: Baseline up to Day 113

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2022; primary completion for Oct 2023, 12 months later.

Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2022
First posted
Jul 20, 2022
StartEst.
Oct 30, 2022
Primary completionEst.
Oct 30, 2023
CompletionEst.
Oct 30, 2023
Last update
Jul 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05465707
Responsible party
Sponsor
First posted
Jul 20, 2022
Start date
Oct 30, 2022 (estimated)
Primary completion
Oct 30, 2023 (estimated)
Completion
Oct 30, 2023 (estimated)
Last update
Jul 20, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumrotatug

Start the discussion